Skip to main content

The independent medical news service

27-01-2023 | Oncology | News | Article

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

Click through for the details of these evidence-based recommendations

26-01-2023 | Oncology | News | Article

Adding camrelizumab to chemo prolongs OS of patients with advanced nonsquamous NSCLC

An updated analysis of the CameL trial has shown a significant improvement in overall survival with the addition of camrelizumab to chemotherapy in treatment-naïve Chinese patients with advanced nonsquamous non-small-cell lung cancer.

23-01-2023 | Oncology | News | Article

ESMO releases guideline for metastatic NSCLC without oncogenic drivers

More information about this Clinical Practice Guideline available here

20-01-2023 | Oncology | News | Article

IL-7 genetic variant linked to ICI toxicity

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

12-01-2023 | Oncology | News | Article

CROWN update confirms long-term lorlatinib PFS benefit

Lorlatinib offers a “durable benefit” for the first-line treatment of advanced ALK-positive non-small-cell lung cancer, indicates a 3-year update from the CROWN trial.

19-12-2022 | Oncology | News | Article

Obesity may increase irAE risk among nivolumab-treated patients

A pooled analysis of clinical trial data points to a link between obesity and an increased risk for any-grade immune-related adverse events among people receiving nivolumab monotherapy for advanced cancer.